Eventide Healthcare & Life Sciences Fd Cl N (ETNHX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Eventide Healthcare & Life Sciences Fd Cl N (ETNHX) trades at $59.18 with AI Score 56/100 (Grade B). Eventide Healthcare & Life Sciences Fd Cl N is a non-diversified, open-end management investment company. Market cap: $1.95B, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for ETNHX: ETNHX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ETNHX against Financial Services peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ETNHX: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Eventide Healthcare & Life Sciences Fd Cl N (ETNHX) Financial Services Profile
Eventide Healthcare & Life Sciences Fd Cl N is an asset management firm specializing in the healthcare and life sciences sectors. The fund invests in companies of any market capitalization, both domestically and internationally, through equity and equity-related securities, including ADRs, to achieve long-term capital appreciation.
What Is the Investment Thesis for ETNHX?
Eventide Healthcare & Life Sciences Fd Cl N presents a focused investment opportunity within the growing healthcare and life sciences sectors. With a beta of 1.27, the fund exhibits slightly higher volatility compared to the market. The fund's strategy of investing at least 80% of its assets in healthcare and life sciences companies positions it to benefit from the sector's long-term growth trends, driven by factors such as an aging global population and advancements in medical technology. The fund's ability to invest in companies of any market capitalization and across international markets provides diversification and access to a wider range of opportunities. However, the fund's non-diversified nature increases its susceptibility to sector-specific risks. The absence of a dividend yield may deter some income-seeking investors.
Based on FMP financials and quantitative analysis
ETNHX Key Highlights
The fund invests at least 80% of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors.
- Eventide Healthcare & Life Sciences Fd Cl N can invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts (ADRs).
- The fund may invest in securities of companies of any market capitalization.
- The fund has a beta of 1.27, indicating slightly higher volatility compared to the market.
- The fund's market capitalization is $1.25 billion.
Who Are ETNHX's Competitors?
ETNHX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AEMGX Acadian Emerging Markets Investor | $34.50 | +0.47% | $1.87B | — |
| AEMZX Acadian Emerging Markets Portfolio Class I | $34.49 | +0.47% | $1.81B | — |
| AOOIX American Century One Choice 2045 Portfolio - I Class | $19.17 | -0.42% | $1.26B | 44 |
| AROIX American Century One Choice 2045 Portfolio Investor Class | $19.12 | -0.47% | $1.25B | 44 |
| ARWIX American Century One Choice 2025 Portfolio Investor Class | $13.22 | -0.75% | $1.30B | 46 |
| TSLX Sixth Street Specialty Lending, Inc. | $18.77 | +0.37% | $1.78B | 68 |
| CET Central Securities Corp. | $54.21 | -0.90% | $1.60B | 70 |
| GCMG GCM Grosvenor Inc. | $13.47 | -2.25% | $2.52B | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ETNHX's Key Strengths?
Specialized focus on high-growth healthcare and life sciences sectors.
- Global investment mandate allows for diversification and access to international opportunities.
- Flexibility to invest in companies of any market capitalization.
- Experienced investment team with deep industry knowledge.
What Are ETNHX's Weaknesses?
Non-diversified nature increases sector-specific risk.
- Reliance on the performance of the healthcare and life sciences sectors.
- Absence of dividend yield may deter income-seeking investors.
- Higher beta indicates greater volatility compared to the overall market.
What Could Drive ETNHX Stock Higher?
Positive clinical trial results for key portfolio holdings could drive stock prices higher.
- Increasing healthcare spending in developed and emerging markets.
- Advancements in medical technology and biotechnology.
What Are the Key Risks for ETNHX?
Regulatory changes and healthcare policy reforms could negatively impact the profitability of portfolio companies.
- Economic downturns and market volatility could lead to declines in asset values.
- Competition from other asset management firms could reduce market share.
- Sector-specific risks associated with the healthcare and life sciences industries.
What Are the Growth Opportunities for ETNHX?
- Expansion into Emerging Markets: The increasing healthcare expenditure in emerging markets presents a significant growth opportunity. By strategically allocating capital to innovative healthcare and life sciences companies in regions like Asia and Latin America, Eventide Healthcare & Life Sciences Fd Cl N can tap into high-growth markets. The global healthcare market is projected to reach $10 trillion by 2028, with emerging markets contributing a substantial portion of this growth. Timeline: Ongoing.
- Increased Investment in Biotechnology: The biotechnology sector is experiencing rapid innovation, driven by advancements in genomics, personalized medicine, and gene editing. By increasing its allocation to biotechnology companies, Eventide Healthcare & Life Sciences Fd Cl N can capitalize on the potential for high returns from breakthrough therapies and technologies. The global biotechnology market is expected to reach $3.88 trillion by 2030, growing at a CAGR of 12.3%. Timeline: Ongoing.
- Focus on Digital Health Technologies: The adoption of digital health technologies, such as telehealth, remote patient monitoring, and AI-powered diagnostics, is accelerating. By investing in companies that are developing and deploying these technologies, Eventide Healthcare & Life Sciences Fd Cl N can benefit from the growing demand for digital health solutions. The global digital health market is projected to reach $660 billion by 2027, growing at a CAGR of 28.5%. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with healthcare providers, research institutions, and other industry players can provide Eventide Healthcare & Life Sciences Fd Cl N with access to valuable insights, deal flow, and co-investment opportunities. These partnerships can enhance the fund's ability to identify and invest in promising healthcare and life sciences companies. Timeline: Ongoing.
- Development of Thematic Investment Products: Creating new investment products focused on specific themes within healthcare and life sciences, such as precision medicine, aging technologies, or infectious disease control, can attract new investors and diversify the fund's assets under management. These thematic funds can cater to investors with specific interests and investment goals. Timeline: Ongoing.
What Are ETNHX's Competitive Advantages?
- Specialized Expertise: Deep understanding of the healthcare and life sciences sectors.
- Global Investment Reach: Ability to invest in companies worldwide through ADRs and direct investments.
- Flexible Investment Mandate: Can invest in companies of any market capitalization.
What Does ETNHX Do?
Eventide Healthcare & Life Sciences Fd Cl N is a non-diversified, open-end management investment company that directs its investments towards the healthcare and life sciences sectors. The fund's strategy involves investing at least 80% of its net assets, along with any borrowings for investment purposes, in the equity and equity-related securities of companies operating within these sectors. This includes common stock, options, preferred stock, and convertible debt. The fund has the flexibility to invest in companies of any market capitalization, allowing it to tap into both established and emerging players in the healthcare and life sciences industries. Eventide Healthcare & Life Sciences Fd Cl N can invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts (ADRs). This global approach enables the fund to access a broader range of investment opportunities and potentially enhance its returns by capitalizing on international healthcare and life sciences trends. The fund aims to provide investors with long-term capital appreciation by focusing on companies that demonstrate strong growth potential and innovation within these critical sectors. The fund's investment decisions are guided by in-depth research and analysis of the healthcare and life sciences landscape, seeking to identify companies with sustainable competitive advantages and the potential to generate significant value for shareholders.
What Products and Services Does ETNHX Offer?
- Invests primarily in equity and equity-related securities.
- Focuses on companies within the healthcare and life sciences sectors.
- Invests at least 80% of net assets in healthcare and life sciences companies.
- May invest in companies of any market capitalization.
- Can invest in securities of companies domiciled outside the United States.
- Utilizes American Depositary Receipts (ADRs) for international investments.
How Does ETNHX Make Money?
- Generates revenue through management fees charged on assets under management (AUM).
- Aims to achieve long-term capital appreciation for its investors.
- Employs a research-driven investment approach to identify promising healthcare and life sciences companies.
What Industry Does ETNHX Operate In?
Eventide Healthcare & Life Sciences Fd Cl N operates within the asset management industry, focusing specifically on the healthcare and life sciences sectors. These sectors are experiencing robust growth, driven by factors such as an aging global population, increasing healthcare spending, and advancements in biotechnology and pharmaceuticals. The competitive landscape includes other asset management firms offering healthcare-focused funds, each with varying investment strategies and risk profiles. The fund's ability to invest globally and across market capitalizations differentiates it from some competitors, providing access to a broader range of investment opportunities.
Who Are ETNHX's Key Customers?
- Individual investors seeking exposure to the healthcare and life sciences sectors.
- Institutional investors looking for specialized investment strategies.
- Retirement plans and endowments seeking long-term growth opportunities.
Eventide Healthcare & Life Sciences Fd Cl N (ETNHX) Valuation Context
Valued at $1.95B, ETNHX is classified as a small-cap stock. Relative to its peer group, ETNHX's quantitative score of 56/100 is above the peer average of 45/100.
Key Financial Metrics
Return on equity for Eventide Healthcare & Life Sciences Fd Cl N stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. ETNHX trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
ETNHX Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying could signal confidence in Eventide's long-term strategy and portfolio holdings, suggesting the company is undervalued.
- The healthcare sector is generally considered defensive, and with an aging population, demand for healthcare services is likely to remain robust, benefiting Eventide.
- Community sentiment indicates a belief in the fund's ethical investment approach, which resonates with a growing segment of investors.
- Positive developments in the life sciences sector, such as breakthroughs in drug development, could positively impact the fund's performance.
Bear Case
- Broader market volatility and economic uncertainty could lead to increased risk aversion, causing investors to pull back from sector-specific funds like Eventide.
- Negative community sentiment regarding potential regulatory changes in the healthcare industry could create headwinds for the fund's holdings.
- Competition from other healthcare and life sciences funds could limit Eventide's ability to attract new capital and maintain its market share.
- Recent market perception suggests concerns about the high valuation of some biotech companies, which could negatively impact Eventide's portfolio.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ETNHX Latest News
No recent news available for ETNHX.
ETNHX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ETNHX.
Price Targets
Wall Street price target analysis for ETNHX.
ETNHX MoonshotScore
What does this score mean?
The MoonshotScore rates ETNHX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
What Investors Ask About Eventide Healthcare & Life Sciences Fd Cl N (ETNHX) — Financial Services
What does the AI Score mean for ETNHX?
ETNHX holds an AI Score of 56/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Eventide Healthcare & Life Sciences Fd Cl N is a non-diversified, open-end management investment company. The fund focuses on investing in equity and equity-related securities within the healthcare …
What does Eventide Healthcare & Life Sciences Fd Cl N do?
Eventide Healthcare & Life Sciences Fd Cl N is an investment fund that focuses on investing in companies within the healthcare and life sciences sectors. The fund aims to achieve long-term capital appreciation by investing at least 80% of its net assets in equity and equity-related securities of companies operating in these sectors.
What are the main risks for ETNHX?
The main risks for Eventide Healthcare & Life Sciences Fd Cl N include sector-specific risks associated with the healthcare and life sciences industries, such as regulatory changes, patent expirations, and product liability lawsuits. The fund's non-diversified nature increases its susceptibility to these risks. Additionally, economic downturns and market volatility could negatively impact the fund's performance.
How does Eventide Healthcare & Life Sciences Fd Cl N manage risk?
Eventide Healthcare & Life Sciences Fd Cl N manages risk through diversification across different companies and sub-sectors within the healthcare and life sciences industries. The fund's investment team conducts in-depth research and analysis to identify companies with strong fundamentals and sustainable competitive advantages.
What regulatory challenges does Eventide Healthcare & Life Sciences Fd Cl N face?
As an asset management firm, Eventide Healthcare & Life Sciences Fd Cl N faces regulatory challenges related to compliance with securities laws and regulations, including those established by the Securities and Exchange Commission (SEC). The fund must adhere to strict guidelines regarding investment disclosures, reporting requirements, and investor protection.
What are the key factors to evaluate for ETNHX?
Eventide Healthcare & Life Sciences Fd Cl N (ETNHX) holds an AI score of 56/100 (moderate). Eventide Healthcare & Life Sciences Fd Cl N presents a focused investment opportunity within the growing healthcare and life sciences sectors. Not financial advice.
How frequently does ETNHX data refresh on this page?
ETNHX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ETNHX's recent stock price performance?
Eventide Healthcare & Life Sciences Fd Cl N (ETNHX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on high-growth healthcare and life sciences sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ETNHX overvalued or undervalued right now?
Eventide Healthcare & Life Sciences Fd Cl N (ETNHX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for ETNHX, some information may be incomplete.